Calcium pyrophosphate deposition disease linked to increased odds of RA, osteoporosis, hypomagnesemia

Calcium pyrophosphate deposition disease appears to be positively associated with increased odds of rheumatoid arthritis, hypomagnesemia and osteoporosis, according to findings.

Researchers reviewed the Department of VA Corporate Data Warehouse to identify 25,157 patients with Calcium pyrophosphate deposition disease (CPDD) and who presented during a 4-year period. Patients with CPDD were sex- and age-matched with control patients without CPDD. Using multivariate analysis, the researchers compared the rate and odds ratios (ORs) of various comorbid conditions, substance use, exposures to medication and arthroplasties among patients with vs. without CPDD.

The point prevalence of CPDD was 5.2 per 1,000. The mean age was 68.1 years and 95% of these patients were male. Researchers found the following to have the strongest positive associations with CPDD: hyperparathyroidism (OR: 3.35); gout (OR: 2.82); osteoarthritis (OR: 2.26); rheumatoid arthritis (OR: 1.88); and hemochromatosis (OR: 1.87). Researchers also found positive associations between CPDD and higher odds of osteoporosis (OR: 1.26), hypomagnesemia (OR: 1.23), chronic kidney disease (OR: 1.12) and calcium supplementation (OR: 1.15). Inverse associations were identified between CPDD and exposure to proton pump inhibitors (OR: 0.58) and loop diuretics (OR: 0.80).

“Using a large national data set, we confirmed known associations with CPDD, provided support for positive associations with rheumatoid arthritis, hypomagnesemia and osteoporosis, and suggested potential novel negative associations with commonly used medications,” the researchers wrote. -by Jennifer Byrne

Disclosures: The study was supported by a U.S. Department of Veterans Affairs VA Merit Review Grant (AKR 101 CX001143). Please see the full study for a list of the authors’ relevant financial disclosures.

Published by:

Sources/Disclosures

Collapse

Source:

Balderrama CK, et. Arthritis Care & Res. 2017;doi:10.1002/acr.23160.